Trial document





This trial has been registered retrospectively.
drksid header

  DRKS00008573

Trial Description

start of 1:1-Block title

Title

Healthcare research multiple myeloma - analysis in patient referring physician and participation satisfaction concerning the interdisciplinary CCF MM-tumorboard.

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

[---]*

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Tumor boards (TB) have become a crucial institution in oncology practice. They ensure paramount interdisciplinary cancer treatment according to clinical pathways, continues cancer education and are required to obtain fund. We have initiated a Multiple Myeloma (MM)-TB in 6/2012, held weekly. The participating experts are hematologist-oncologists, orthopedic surgeons, radiologists, radiotherapists, pathology, cytogenetic specialists, and depending on pt-specific problems: nephrologists, cardiologists and others. Recommendation on diagnostics, treatment and pt care advice are made according to local and international guidelines and literature to ensure state of the art treatment. This analysis was designed to evaluate the satisfaction of MM-pts with the MM-TB. Brief standardized questionnaires were specifically adapted.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

This analysis was designed to evaluate the satisfaction of multiple myeloma (MM) patients with the MM-Tumorboard (TB). Brief standardized questionnaires were specifically adapted and discussed with 3 panel: MM-TB-group, Comprehensive Cancer Center (CCCF) and our statisticans.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00008573
  •   2015/05/21
  •   [---]*
  •   yes
  •   Approved
  •   20/15, Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   C90.0 -  Multiple myeloma
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Tumor boards (TB) have become a crucial institution in oncology practice. They ensure paramount interdisciplinary cancer treatment according to clinical pathways, continues cancer education and are required to obtain fund. We have initiated a Multiple Myeloma (MM)-TB in 6/2012, held weekly. The participating experts are hematologist-oncologists, orthopedic surgeons, radiologists, radiotherapists, pathology, cytogenetic specialists, and depending on pt-specific problems: nephrologists, cardiologists and others. Recommendation on diagnostics, treatment and pt care advice are made according to local and international guidelines and literature to ensure state of the art treatment. This analysis was designed to evaluate the satisfaction of MM-pts with the MM-TB. Brief standardized questionnaires were specifically adapted.
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Observational study
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Health care system
  •   Single (group)
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Evaluate the satisfaction of MM-Patients with standardized questionnaires at the moment of indication of therapy.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

none

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2014/03/03
  •   100
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Patients with multiple myeloma

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

none

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Universitätsklinikum Freiburg
    • Hugstetter Strasse 49
    • 79095  Freiburg
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Uniklinik Freiburg
    • Ms.  Prof. Dr. med.  Monika Engelhardt  Engelhardt 
    • Hugstetter Str. 55
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Uniklinik Freiburg
    • Ms.  Prof. Dr. med.  Monika Engelhardt  Engelhardt 
    • Hugstetter Str. 55
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Uniklinik Freiburg
    • Ms.  Prof. Dr. med.  Monika Engelhardt  Engelhardt 
    • Hugstetter Str. 55
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up complete
  •   2014/12/19
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.